n-hydroxy-n--(4-butyl-2-methylphenyl)formamidine and Kidney-Neoplasms

n-hydroxy-n--(4-butyl-2-methylphenyl)formamidine has been researched along with Kidney-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for n-hydroxy-n--(4-butyl-2-methylphenyl)formamidine and Kidney-Neoplasms

ArticleYear
Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth.
    Anticancer research, 2009, Volume: 29, Issue:10

    We examined the ability of inhibitors of the synthesis or actions of 20-HETE, metabolite of arachidonic acid, to inhibit proliferation of human renal carcinoma cell lines.. 786-O and 769-P cells were exposed to either 10 microM HET0016 (selective inhibitor of 20-HETE synthesis), 10 microM WIT002 (20-HETE antagonist), or vehicle. Subsequently, we assessed the effect of WIT002 on tumor growth in vivo using an ectopic mouse model of clear-cell renal carcinoma.. Addition of HET0016 and WIT002 inhibited the proliferation of 786-O and 769-P human renal cell carcinoma lines. HET0016 and WIT002 had little effect on the proliferation of primary cultures of normal human proximal tubule epithelial cells. WIT002 (10 mg/kg, s.c.) administered daily to athymic nude mice implanted subcutaneously with 786-O cells reduced the growth of the tumors by 84 % compared to vehicle (p<0.001).. 20-HETE is required for proliferation of human renal epithelial cancer.

    Topics: Amidines; Animals; Arachidonic Acid; Carcinoma, Renal Cell; Cell Growth Processes; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Down-Regulation; Humans; Hydroxyeicosatetraenoic Acids; Kidney Neoplasms; Mice; Mice, Nude; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2009